Biotech Company Uses CRISPR to Edit Cholesterol Gene
July 20, 2022| |
A patient in New Zealand is the first to undergo DNA editing to lower their blood cholesterol as part of a clinical trial by the U.S. biotechnology company Verve Therapeutics. A version of the gene editing tool CRISPR was injected to modify a single letter of DNA in the patient's liver cells.
Verve Therapeutics said that the tiny edit should be enough to permanently lower a person's levels of “bad” LDL cholesterol, the fatty molecule that causes arteries to clog and harden with time. The gene that Verve is editing is called PCSK9. It has a big role in maintaining LDL levels, and the company says the gene will be turned off by introducing a one-letter misspelling.
The clinical trial in New Zealand will give the gene treatment to 40 people who have an inherited form of high cholesterol known as familial hypercholesterolemia, or FH. People with FH can have twice the average cholesterol readings, even as children. The study also marks the early use of base editing, a CRISPR adaptation first developed in 2016 that substitutes a single letter of DNA for another, unlike traditional CRISPR which cuts a gene.
For more details, read the article in MIT Technology Review.
| |
You might also like:
- First CRISPR Drug Coming Soon
- WHO Releases Framework for Governance of Human Genome Editing
- Chinese Scientists Test CRISPR Gene-editing in Human for the First Time
Biotech Updates is a weekly newsletter of ISAAA, a not-for-profit organization. It is distributed for free to over 22,000 subscribers worldwide to inform them about the key developments in biosciences, especially in biotechnology. Your support will help us in our mission to feed the world with knowledge. You can help by donating as little as $10.
-
See more articles:
-
Gene Editing Supplement (July 20, 2022)
-
Research and Tools
- Experts Boost Plant Immunity to Face Warming Temperatures
- Study Gauges Public Acceptance of Gene-edited Foods
- SCNT-CRISPR-Cas9 Combo Successfully Produces Genome-edited Dogs
- Biotech Company Uses CRISPR to Edit Cholesterol Gene
-
Public Acceptance and Engagement
- High School Teachers Tackle CRISPR in Biotech Classes
- Experts Highlight Gene Editing Potentials for Vietnam’s Agri Sector
-
Read the latest: - Biotech Updates (April 17, 2024)
- Gene Editing Supplement (April 10, 2024)
- Gene Drive Supplement (February 22, 2023)
-
Subscribe to BU: - Share
- Tweet